FDA

Dear Research Advocate, This Saturday, advocates will celebrate science at events in Washington, D.C., and hundreds of cities across the globe to call attention to the value of science -- how it impacts our health, economy and planet. I encourage you to participate in the March for Science in your local communities and help us raise awareness of scientific progress. Our new video featuring one of our science fellows will be shown on jumbotrons on the National Mall in D.C. during the event. Read more about this celebration in our Board Chair’s statement , my op-ed in the Miami Herald and an LTE by Research!America’s Suzanne Ffolkes in the Hartford Courant. The March is the beginning of a...
Dear Research Advocate, OMB has recommended cuts to FY17 appropriations , which would precede, if you will, the proposed FY18 cuts. As noted in our statement , these proposed cuts contradict worthy goals the President established for his tenure in office. They also fly in the face of public opinion. Fortunately, it appears Congress is not playing ball . Please use this editable message to say no to reductions and yes to passage of an FY17 omnibus bill. Reliable sources say the bill includes a $2 billion boost for NIH, as well as increases for CDC, FDA and NSF. The media is chock-full of commentary and quotes supporting investment in research and public health. A masterful Washington Post op...
Dear Research Advocate, House Republican Leadership released an ACA replacement bill this week (section summaries available from the Energy & Commerce and Ways & Means committees). The bill has been creating waves, concerning many in the public health and health care fields. The cost and coverage impact have yet to be estimated, but we do know that the bill repeals the Prevention and Public Health Fund (PPHF), which accounts for approximately 12% of CDC’s budget. House Labor-H Chairman Cole (R-OK) discussed CDC’s crucial role in a recent STAT article. Use this editable message to make the case for CDC and PPHF. Trust for America’s Health is a terrific resource for more background...
Dear Research Advocate, I have exciting news! Joe Biden, the 47th Vice President of the United States, will join us at our 21st Annual Advocacy Awards Dinner on March 15 to receive the Gordon and Llura Gund Leadership Award . As he has demonstrated through his leadership of the Cancer Moonshot Initiative, his work in Congress, and in so many other ways, the former Vice President is a true advocate for research. Join us for a remarkable evening. A foundational goal for this annual event is to spotlight advocates for science -- often those who both practice and champion it -- as embodying the “secret sauce” that empowers science by driving public and policymaker support. More scientists are...
Dear Research Advocate, Tomorrow, our 45th U.S. President will be inaugurated. The challenge and opportunity that President Trump - and all our elected representatives - face is to ensure that the next four years deliver better health, safety and prosperity. I hope President Trump’s inaugural address signals that his Administration will leverage research and innovation to meet our nation’s normative and strategic objectives. With NIH, CDC, AHRQ and FDA under the purview of the Department of Health and Human Services, the new Secretary will influence the nature and pace of medical progress, the capability of our public health infrastructure, and other critical science-relevant variables in...
Dear Research Advocate, On Tuesday, I had the great honor of attending the bill signing for the 21st Century Cures Act (21stCC). It was particularly meaningful that this bill crossed the finish line during Vice President Biden’s tenure. His determination to deliver other families from the cancer tragedy experienced by his own lent a special strength to our collective efforts over a protracted period of congressional debate. If we continue to channel the Vice President’s level of commitment and determination, we can ensure that achieving faster medical progress remains at the forefront of national priorities. As you know (but it never hurts to reaffirm), it is important, but not sufficient,...
Dear Research Advocate, As we prepare to celebrate Thanksgiving, it is fitting to thank our public health workforce for their tireless efforts on our behalf every day of the year. Monday marked the official Public Health Thank You Day (PHTYD), but it is ongoing. This year’s effort has been extraordinary, with more than 50 organizations partnering with us to get the word out. For the first time since we launched PHTYD in 2005, Congress officially joined the effort. As I mentioned last week, the co-chairs of the House Public Health Caucus introduced a resolution supporting PHTYD. Online, more than 1,000 organizations and individuals participated, including federal officials from HHS and DOD,...
Watch the videos from each panel, read the transcript , view the photo gallery and read the WebMD live recap . “The biomedical research enterprise underpins the health of the nation and much of the world, and is in dire need of substantial infusion to meet the great medical needs of our time,” said William N. Hait, M.D., Ph.D. , global head, Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the keynote speaker at the 2016 National Health Research Forum, added that we’re losing time in addressing threats like the Zika virus, Ebola and cancer while waiting for funding to improve for biomedical research. The program, held Thursday,...
Partnerships between patient groups, industry, government and academia are accelerating the research and development of new treatments for rare diseases, many of which have no effective therapies. As a result of the Food and Drug Administration’s (FDA) Orphan Drug Designation, eligible companies receive incentives for product development such as tax credits for qualified clinical testing and new drugs are reaching patients sooner. Since 1983, more than 400 drugs and biologic products for rare diseases have been developed, far outpacing the number of products that were available some 40 years ago. Amyotrophic lateral sclerosis (ALS) is among the nearly 7,000 rare diseases where very few...
Dear Research Advocate: Earlier this week, the House passed an inadequate proposal for $622.1 million in emergency Zika funding, falling far short of the bipartisan Senate proposal of $1.1 billion passed this week, not to mention the President’s request of $1.9 billion. Appropriations subcommittee Chairman Cole (R-OK-04) has stated that subsequent Zika funding will come in the next appropriations cycle, but public health experts tell us we cannot wait. (This is especially true since the pattern of the last many years is for appropriations to go undetermined until almost calendar year end.) Summer months are approaching and half the continental U.S. is home to potential disease-carrying...

Pages

Sidebar Quote

Without research, there is no hope.
The Honorable Paul G. Rogers